NAA10 and NAT2

Number of citations of the paper that reports this interaction (PubMedID 12888564)
31

Data Source:
HPRD (in vitro)

		NAA10	NAT2
Description		N-alpha-acetyltransferase 10, NatA catalytic subunit	N-acetyltransferase 2
Image
GO Annotations	Cellular Component	Nucleus Nucleolus Cytoplasm Cytosol Membrane NatA Complex	Cytosol
	Molecular Function	Peptide Alpha-N-acetyltransferase Activity Protein Binding N-acetyltransferase Activity Acetyltransferase Activity Ribosome Binding Peptide-serine-N-acetyltransferase Activity Peptide-glutamate-N-acetyltransferase Activity	Arylamine N-acetyltransferase Activity Protein Binding
	Biological Process	DNA Packaging Protein Acetylation N-terminal Protein Amino Acid Acetylation Internal Protein Amino Acid Acetylation N-terminal Peptidyl-serine Acetylation N-terminal Peptidyl-glutamic Acid Acetylation Negative Regulation Of Maintenance Of Mitotic Sister Chromatid Cohesion, Centromeric	Xenobiotic Metabolic Process
Pathways			Acetylation
Drugs
Diseases
GWAS		Systemic lupus erythematosus ( 26502338)	Apolipoprotein A1 levels ( 32203549) Apolipoprotein B levels ( 32203549) Bladder cancer ( 24163127 20972438) Blood metabolite levels ( 24816252) Blood metabolite ratios ( 24816252) Cholesterol, total ( 24097068 20686565) Coronary artery disease ( 29212778 33020668) Gut microbiota (bacterial taxa, hurdle binary method) ( 32572223) Insulin resistance/response ( 25798622) Iron status biomarkers (total iron binding capacity) ( 33536631) Iron status biomarkers (transferrin levels) ( 25352340) LDL cholesterol levels ( 32203549) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Liver enzyme levels (alkaline phosphatase) ( 33972514) Liver enzyme levels (gamma-glutamyl transferase) ( 33972514) Liver injury in anti-tuberculosis drug treatment ( 31109976) Medication use (calcium channel blockers) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Metabolic syndrome ( 31589552) Metabolic traits ( 21886157) Metabolite levels ( 23823483) Myocardial infarction ( 33532862) Night sleep phenotypes ( 27126917) Paclitaxel-induced neuropathy ( 23776197) Serum metabolite levels ( 33031748) Total cholesterol levels ( 28334899 33339817) Triglyceride levels ( 32203549 28334899 29403010 33339817 30698716) Triglyceride levels in current drinkers ( 30698716) Triglyceride levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) Triglyceride levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Triglyceride levels x long total sleep time interaction (2df test) ( 31719535) Triglyceride levels x short total sleep time interaction (2df test) ( 31719535) Triglycerides ( 24097068 20686565) Urinary metabolite levels in chronic kidney disease ( 31959995) Urinary metabolite modules (eigenmetabolites) in chronic kidney disease ( 31959995) Urinary metabolites ( 26352407 21572414) Urinary metabolites (H-NMR features) ( 24586186) Youthful appearance (self-reported) ( 32339537)
Interacting Genes		55 interacting genes: ACOT12 BAALC BCOR CALCOCO2 CASP8AP2 CCDC106 CCDC174 CDC25A CDCA5 CEP44 CREB3 CREBRF DDIT4L DHX57 EHMT2 FIP1L1 GPATCH2L HIF1A HIF1AN HSPA4 KIFAP3 KRTAP10-3 KRTAP10-5 KRTAP10-6 KRTAP10-7 MCRS1 MDM4 MEOX2 MKRN1 MRPS11 NAA15 NAA16 NAA50 NAT1 NAT2 NOXA1 PDE4DIP PGK1 PLSCR3 PPP2R3B PSME2 RAB3IP RBCK1 RCN3 RIMBP2 RPL26 SEMA3B SNX33 SSX2IP TAF7L TSEN54 UBC ZBTB14 ZNF202 ZNF655	18 interacting genes: APC APP AURKA BAG4 CDKN2A CDKN2C CLU ERBB2 FZR1 HMMR IGF1R MBD4 NAA10 NBN PALB2 PPM1D STK11 WT1
Entrez ID		8260	10
HPRD ID		02056	02000
Ensembl ID		ENSG00000102030	ENSG00000156006
Uniprot IDs		B7Z9N2 P41227	A4Z6T7 P11245
PDB IDs		6C95 6C9M 6PPL 6PW9	2PFR
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?